Loading company…
ID 439394264 · FY 2019–2024 · 6 years
კომპანიის ძირითად საქმიანობას წარმოადგენს საბითუმო ვაჭრობა ფარმაცევტული საქონლით.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Ratio | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Margins | ||||||
| Gross Margin | 69.0% | 67.7% | 64.5% | 69.2% | 74.8% | 69.9% |
| EBITDA Margin | 51.9% | 51.8% | 49.9% | 53.4% | 60.0% | 50.1% |
| EBITDAR | 1,120 | 1,369 | 2,056 | 2,556 | 3,915 | 2,980 |
| EBITDAR Margin | 51.9% | 51.8% | 49.9% | 53.4% | 60.0% | 50.1% |
| EBIT Margin | 50.9% | 50.8% | 49.2% | 52.8% | 59.1% | 49.1% |
| Net Profit Margin | 46.5% | 46.9% | 43.7% | 44.9% | 50.5% | 44.4% |
| Operating Expense % of Sales | 17.0% | 15.9% | 14.6% | 15.8% | 14.8% | 19.8% |
| Returns | ||||||
| Return on Assets (ROA) | 59.1% | 52.0% | 53.9% | 49.8% | 53.4% | 34.2% |
| Return on Equity (ROE) | 59.1% | 52.1% | 54.4% | 50.1% | 53.4% | 34.2% |
| ROIC [EBIT / Invested Capital] | 66.6% | 59.2% | 69.8% | 71.0% | 76.6% | 54.4% |
| Leverage & liquidity | ||||||
| Debt-to-Assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt-to-Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Equity-to-Assets | 100.0% | 99.9% | 99.1% | 99.4% | 100.0% | 100.0% |
| Net Debt | -52 | -112 | -407 | -738 | -1,134 | -2,353 |
| Cash & Equivalents | 52 | 112 | 407 | 738 | 1,134 | 2,353 |
| Total Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Efficiency & working capital | ||||||
| Inventory Turnover | 2.71x | 1.26x | 1.85x | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | 134.8 | 289.2 | 197.5 | N/A | N/A | N/A |
| Receivables Turnover | 2.19x | 2.08x | 2.25x | 2.06x | 1.99x | 2.04x |
| Days Sales Outstanding (DSO) | 166.9 | 175.8 | 162.5 | 177.2 | 183.0 | 179.2 |
| Payables Turnover | 1514.62x | 283.88x | 48.26x | 55.31x | N/A | N/A |
| Days Payable Outstanding (DPO) | 0.2 | 1.3 | 7.6 | 6.6 | N/A | N/A |
| Cash Conversion Cycle | 301.4 days | 463.7 days | 352.5 days | 170.6 days | 183.0 days | 179.2 days |
| Asset Turnover | 1.27x | 1.11x | 1.23x | 1.11x | 1.06x | 0.77x |
| Cash flow & dividends | ||||||
| Operating Cash Flow | N/A | N/A | N/A | 331 | 396 | 1,219 |
| Free Cash Flow (OCF − Capex proxy) | N/A | N/A | N/A | 331 | 396 | 1,219 |
| Cash Conversion (OCF / EBITDA) | N/A | N/A | N/A | 13.0% | 10.1% | 40.9% |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in ₾ '000. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.
Ownership & directors from companyinfo.ge (public corporate registry).